C4 Therapeutics, Inc.
CCCCFigures shown here come from public SEC filings. Dates beside each section show the available history.
How C4 Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 26, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| FMR LLC | 2026-03-31 | 272,368 | $716K | SEC filing |
| Graham Capital Management, L.P. | 2026-03-31 | 23,733 | $62.4K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 9,072,400 | $23.9M | SEC filing |
| Dauntless Investment Group, LLC | 2026-03-31 | 15,000 | $39.5K | SEC filing |
| Hennion & Walsh Asset Management, Inc. | 2026-03-31 | 223,168 | $587K | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 101 | $266 | SEC filing |
| ACADIAN ASSET MANAGEMENT LLC | 2026-03-31 | 1,890,914 | Not shown | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 680 | Not shown | SEC filing |
| Advisory Services Network, LLC | 2026-03-31 | 74 | $195 | SEC filing |
| INTREPID FAMILY OFFICE LLC | 2026-03-31 | 60,000 | $158K | SEC filing |
| RA CAPITAL MANAGEMENT, L.P. | 2026-03-31 | 8,000,000 | $21M | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2026-03-31 | 1,393,342 | $3.66M | SEC filing |
| CANADA PENSION PLAN INVESTMENT BOARD | 2026-03-31 | 135,600 | $357K | SEC filing |
| Fortitude Family Office, LLC | 2026-03-31 | 435 | $1.14K | SEC filing |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2026-03-31 | 264,620 | $696K | SEC filing |
| Blackston Financial Advisory Group, LLC | 2026-03-31 | 10,000 | $26.3K | SEC filing |
| Brevan Howard Capital Management LP | 2026-03-31 | 92,647 | $244K | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 2,048,526 | $5.39M | SEC filing |
| OMERS ADMINISTRATION Corp | 2026-03-31 | 59,700 | $157K | SEC filing |
| Schonfeld Strategic Advisors LLC | 2026-03-31 | 23,944 | $63K | SEC filing |
- Each value is checked against C4 Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at C4 Therapeutics, Inc.'s share price.
- Value not shown for 1 row: the value per share could not be confirmed against the share prices on file from within three months of the report date.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- SUSQUEHANNA INTERNATIONAL GROUP, LLP: 1,775,783 shares reported 2025-12-31; 1,286,840 shares reported 2026-03-31.
118 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-01-16 | REYNO LEONARD · Chief Medical Officer | Common Stock | S — Open market or private sale | −10,000 | 2.22 | SEC filing |
| 2025-02-18 | Boyle Scott N · Chief Business Officer | Common Stock | S — Open market or private sale | −669 | 3.15 | SEC filing |
| 2025-02-14 | Boyle Scott N · Chief Business Officer | Common Stock | S — Open market or private sale | −490 | 3.15 | SEC filing |
| 2023-02-08 | Koppikar Utpal · Director | Common Stock | P — Open market or private purchase | +5,667 | 5.60 | SEC filing |
Showing 4 of 4 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-24 | Anderson Kenneth Carl · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
| 2026-06-24 | Cooper Ronald Harold Wilfred · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
| 2026-06-24 | GROGAN DONNA ROY · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
| 2026-06-24 | Hughes Owen · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
| 2026-06-24 | Koppikar Utpal · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
| 2026-06-24 | Bessen Laura · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
| 2026-06-24 | Fawell Stephen · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
| 2026-06-24 | Hoerter Steven L. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +62,000 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-03-07 | Fisher Stewart · Chief Scientific Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −118,000 | SEC filing |
| 2024-03-07 | Boyle Scott N · Chief Business Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −115,000 | SEC filing |
| 2024-03-07 | Schick Kelly · Chief People Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −78,500 | SEC filing |
| 2024-03-07 | Fisher Stewart · Chief Scientific Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −94,950 | SEC filing |
| 2024-03-07 | Adams Kendra · Chief Financial Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −45,000 | SEC filing |
| 2024-03-07 | Schick Kelly · Chief People Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −92,000 | SEC filing |
| 2024-03-07 | Siegel Jolie · Chief Legal Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −84,850 | SEC filing |
| 2024-03-07 | Siegel Jolie · Chief Legal Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −90,000 | SEC filing |
Showing 8 of 8 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.